Publicador de contenidos

Investigación, Salud Materna, Infantil y Reproductiva

SARA (SARS-CoV-2 and Acetylsalicylic acid)

Efficacy of low dose acetylsalicylic acid in preventing adverse maternal and perinatal outcomes in SARS-CoV-2 infected pregnant women

SARA (SARS-CoV-2 and Acetylsalicylic acid)
01/01/2023 - 31/12/2025
Clara Menéndez
FIS-Instituto de Salud Carlos III

SARS-CoV-2 infection in pregnancy is associated with an increased risk of adverse maternal and perinatal outcomes. One explanation is that the infection might increase the existing pregnancy-associated prothrombotic status, leading to a higher risk of placental and vascular complications.

Administration of low-dose acetylsalicylic acid (LDASA) has shown to improve maternal and perinatal outcomes in women at high-risk of endothelial and placental complications. However, there are no data on the effect of LDASA in preventing complications in SARS-CoV-2- infected pregnant women.


To reduce SARS-CoV-2- related complications in a highly vulnerable group to the infection, we will carry out this randomized, double-blind, placebo-controlled multicentre trial in 400 SARS-CoV-2-infected pregnant women.

The study main objective is to evaluate the efficacy and safety of LDASA administered up to 36 weeks of gestation in SARS-CoV-2-infected pregnant women in reducing the incidence of adverse maternal and perinatal outcomes.

Pregnant women tested positive up to 32 weeks of gestation with a SARS-CoV-2 rapid antigen or PCR test and agreeing to participate, will be randomised 1:1 to receive daily LDASA (125 mg) or placebo up to 36 weeks of gestation and be followed-up until delivery.

Total Funding

153,670 €

Nuestro equipo


  • Clara Menéndez Santos
    Clara Menéndez Santos

ISGlobal Team

Otros proyectos

Ver proyectos pasados


Validación continuada de la autopsia mínimamente invasiva (MIA) para la investigación de la causa de muerte en niños pequeños, y desarrollo de un centro de investigación y formación sobre el estudio de la causa de muerte


Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women


Improving Care through Azithromycin Research for Infants in Africa


Identification of Prematurity and Pre-Eclampsia as Causes of Mortality


MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention


Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations


Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone


Respiratory syncytial virus (RSV) in African pregnant women and children


Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance

HIV drug resistance (HIVDR)

Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique